Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Toxoplasma gondii apical membrane antigen-1

a technology of apical membrane and antigen, which is applied in the field of tgama1-based animal and human vaccines, can solve the problems of acute toxoplasmosis, death, mental retardation, etc., and achieve the effect of reducing the likelihood of a toxoplasma infection

Inactive Publication Date: 2005-09-22
UNIVERSITY OF VERMONT +1
View PDF3 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0021] According to yet another aspect of the invention, methods for reducing the likelihood of a toxoplasma infection are provided. The methods include administering to a subject in need of such treatment, an effective amount of a foregoing TgAMA-1 binding polypeptide to reduce the likelihood of toxoplasma infection. In some embodiments, the TgAMA-1 binding polypeptide blocks the entry of Toxoplasma parasite into a cell. In some embodiments, the subject is a mammal. In certain embodiments, the subject is a human.

Problems solved by technology

The infection tends to be self-limiting, with the individual's immune system controlling and eliminating most of the parasites.
In the fetus, toxoplasma infection can cause mental retardation, visual defects, and death.
Acute toxoplasmosis can be difficult to treat.
The toxic and potentially teratogenic effects of this regimen make management of the pregnant woman particularly problematic.
AIDS patients require lifelong suppressive therapy to prevent relapse, and a many as one third of the patients receiving suppressive sulfadiazine / pyrimethamine therapy cannot tolerate the adverse side effects.
For those who can tolerate the drugs, relapse occurs frequently.
Unfortunately, this alternative combination can also cause considerable toxicity and is less effective at preventing relapse.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

Antibody Generation and Characterization of TgAMA-1

Procedure

Parasite Culture

[0092]T. gondii tachyzoites (RH strain, unless otherwise indicated) were cultured in human foreskin fibroblasts as previously described [5] and filtered through a 10 μm polycarbonate filter (Poretics, Livermore Calif.) prior to use.

Antibodies

[0093] MAbs: MAb B3.90 (against TgAMA-1) and A3.2 (against GRA8) were generated as described [3, 6] and purified by ion exchange and gel filtration chromatography [7]. Ascites fluid containing MAb 6D10 (against MIC2) was prepared as described [1]. Ascites fluid containing MAb Tg49 (against ROP1) was generously provided by Joseph Schwartzman (Dartmouth College, Hanover N.H.). MAb 40-1a (against E. coli β-galactosidase) was developed by J. R. Sanes and obtained from the Developmental Studies Hybridoma Bank (University of Iowa, Department of Biological Sciences, Iowa City Iowa) as a hybridoma supernatant.

[0094] Polyclonal antibody UVT59: A synthetic peptide corresp...

example 2

Expression of AMA-1 in High Five™ Insect Cells

[0117] Recombinant TgAMA-1 and various fragments of TgAMA-1 have been expressed in E. coli, but Western blotting with the conformation-sensitive MAb B3.90 suggested that these recombinant fragments were incorrectly folded. Proper folding of recombinant protein is more likely to be obtained in eukaryotic cell expression systems. To this end, we have recently expressed recombinant TgAMA-1 in insect cells. Using conventional molecular genetic techniques, Toxoplasma AMA-1 coding sequence corresponding to the signal peptide, ectodomain, and the transmembrane domain (amino acid residues 1-473) was amplified from cDNA and ligated into pIZ / V5-His(Invitrogen) in frame with both V5 and His eptiope tags. PIZ / V5-His encodes a Zeocin™ resistance selectable marker gene and the promoter, OpIE2, which drives constitutive expression of the inserted gene. The construct was transformed into E. coli and plasmid DNA was isolated from antibiotic resistant co...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
temperaturesaaaaaaaaaa
pHaaaaaaaaaa
pHaaaaaaaaaa
Login to View More

Abstract

The invention provides polypeptide fragments derived from TgAMA-1, nucleic acids that encode the polypeptide fragments, and TgAMA-binding polypeptides such as antibodies. Methods for using the polypeptide and nucleic acid molecules to produce vaccines are also provided. In addition the invention provides methods involving use of the polypeptides, nucleic acids, and binding polypeptides, such as antibodies, for the prevention and treatment of Toxoplasmosis.

Description

RELATED APPLICATIONS [0001] This application claims priority under 35 U.S.C. §119 to U.S. 60 / 247,870, filed Nov. 9, 2000, the entire contents of which is hereby incorporated by reference.GOVERNMENT SUPPORT [0002] This invention was made in part with government support under grant number R29A142355 from the National Institutes of Health (NIH). The government may have certain rights in this invention.FIELD OF THE INVENTION [0003] The present invention relates to TgAMA-1, and TgAMA-1-based animal and human vaccines for toxoplasmosis. BACKGROUND OF THE INVENTION [0004] Toxoplasmosis is among the most common parasitic diseases of man. Serosurveys suggest prevalence rates as high as 70-90% in many areas of both the developing and developed world. Between 10-45% of Americans become infected at some point in their lives. An infection in an individual with a competent immune system generally has minor or no symptoms. The infection tends to be self-limiting, with the individual's immune syste...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/00A61K39/002A61K39/012C07K14/45C07K16/20
CPCA61K39/00A61K39/002C07K2319/00C07K14/45C07K16/20A61K39/012
Inventor WARD, GARYCONANT, CAROLYNWARD, BRIAN
Owner UNIVERSITY OF VERMONT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com